Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : F. Hoffmann-La Roche
Deal Size : $1,870.0 million
Deal Type : Collaboration
Flare Collaborates with Roche On Oncology Discovery Efforts
Details : Flare will lead discovery and preclinical activities targeting multiple transcription factor targets in oncology, while Roche will pursue preclinical and clinical development and commercialization.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $70.0 million
November 14, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : F. Hoffmann-La Roche
Deal Size : $1,870.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : F. Hoffmann-La Roche
Deal Size : $1,870.0 million
Deal Type : Collaboration
Flare Collaborates with Roche On Undrugged Transcription Factor Targets
Details : The collaboration aims to discover novel small molecule drugs aimed at previously undrugged transcription factor targets in oncology leveraging Flare's proteomic and mass spectrometry platform.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $70.0 million
November 12, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : F. Hoffmann-La Roche
Deal Size : $1,870.0 million
Deal Type : Collaboration
Lead Product(s) : 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : FX-909 is a highly potent and selective inhibitor of PPARG and has demonstrated tumor eradication in preclinical animal models of urothelial cancer at low oral doses.
Brand Name : FX-909
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 19, 2023
Lead Product(s) : 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile
Therapeutic Area : Oncology
Study Phase : IND Enabling
Recipient : Caris Life Sciences
Deal Size : Undisclosed
Deal Type : Partnership
Details : The collaboration focuses to accelerate precision medicine approaches across five of Flare's programs, including its lead precision oncology program, FX-909, a small molecule inhibitor targeting PPARG, into clinical trials through advanced molecular prof...
Brand Name : FX-909
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 13, 2023
Lead Product(s) : 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Recipient : Caris Life Sciences
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : GordonMD Global Investments
Deal Size : $123.0 million
Deal Type : Series B Financing
Flare Therapeutics Announces Oversubscribed $123 Million Series B Financing
Details : The net proceeds will be used to support the advancement of FX-909, a first-in-class PPARG inhibitor, into the clinic in 2023, along with continued development of Flare's platform and pipeline of novel transcription factor targets in oncology.
Brand Name : FX-909
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 22, 2023
Lead Product(s) : 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : GordonMD Global Investments
Deal Size : $123.0 million
Deal Type : Series B Financing
Lead Product(s) : 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Flare is advancing a novel PPARG inhibitor through Investigational New Drug (IND)-enabling studies and expects to initiate its Phase 1 clinical trial for FX-909 in 2023 in individuals with locally advanced or metastatic UC.
Brand Name : FX-909
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 28, 2022
Lead Product(s) : 3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)-4-methylsulfonylbenzonitrile
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : FTX-6746
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : FTX-6746, a potent, selective, small molecule PPARG inhibitor (inverse agonist), drives robust PPARG target gene silencing in UC cell lines and drives tumor regression in PPARG-amplified and RXRA-mutant UC xenograft models.
Brand Name : FTX-6746
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 26, 2022
Lead Product(s) : FTX-6746
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The Series A will support Flare’s further advancement of its lead program in precision oncology toward the clinic. In addition, the company will continue to build its unique engine and proprietary assays to discover small molecules.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 13, 2021
LOOKING FOR A SUPPLIER?